公开(公告)号：WO2011127324A3

公开(公告)日：2012-04-05

申请号：PCT/US2011031640

申请日：2011-04-07

Applicant: JN BIOSCIENCES LLC ,  TSO J YUN ,  TSURUSHITA NAOYA ,  LANDOLFI NICHOLAS F ,  KUMAR SHANKAR

Inventor： TSO J YUN ,  TSURUSHITA NAOYA ,  LANDOLFI NICHOLAS F ,  KUMAR SHANKAR

IPC: C07K16/28 ,  A61K39/395 ,  A61P29/00 ,  A61P35/00 ,  C07K16/18 ,  C07K16/46

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76

Abstract: The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.

Abstract translation: 本发明提供了特异性结合CD122的单克隆抗体，CD122是IL-2和IL-15受体的一个组分。 通过抑制这些细胞因子与其受体的结合，单克隆抗体具有对IL-2和IL-15介导的功能的显着抑制的能力。 除了其它应用之外，单克隆抗体可用于抑制不期望的免疫应答或癌症的治疗。

公开(公告)号：WO2011053819A3

公开(公告)日：2011-10-27

申请号：PCT/US2010054790

申请日：2010-10-29

Applicant: BP CORP NORTH AMERICA INC ,  CUMMINS INC ,  XU YI ,  WOLF LESLIE ,  KUMAR SHANKAR ,  STANTON DONALD W ,  FRAZIER TIMOTHY R ,  BUNTING BRUCE G

Inventor： XU YI ,  WOLF LESLIE ,  KUMAR SHANKAR ,  STANTON DONALD W ,  FRAZIER TIMOTHY R ,  BUNTING BRUCE G

IPC: F02D41/00 ,  C10L1/08

CPC classification number: F02D41/0025 ,  C10L1/08 ,  F02D19/061 ,  F02D19/0649 ,  F02D19/087 ,  F02M26/23 ,  F02M31/13 ,  F02M2200/95 ,  Y02T10/36

Abstract: A diesel fuel composition is disclosed, as well as a method for reducing NOx and smoke emissions from a diesel engine at minimum fuel consumption which comprises adding to the diesel engine at least one diesel fuel or blending component for a diesel fuel which has a combination of a low T50 in the range of from 190°C to 28O°C, a high cetane number in the range of from 31 to 60, and optionally a high distillation curve slope in the range of from 58°C to 140°C, which combination is effective to afford a combination of the lowest NOx and smoke emissions at the lowest fuel consumption at independent engine control values for the diesel engine that are optimum to afford production of a combination of the lowest NOx and smoke emissions at the lowest fuel consumption, whereby the NOx and smoke emissions from the diesel engine are reduced by at least 10% and 15%, respectively.

Abstract translation: 公开了一种柴油燃料组合物，以及一种用于以最小燃料消耗减少柴油发动机的NOx和烟气排放的方法，该方法包括向柴油发动机添加至少一种柴油燃料或柴油燃料的混合组分，其具有 在190℃至280℃范围内的低T 50，在31至60范围内的高十六烷值以及任选地在58℃至140℃范围内的高蒸馏曲线斜率，其中 在最低燃料消耗和最低燃料消耗下最低NOx和烟气排放的组合产生最佳的柴油发动机的独立发动机控制值时，组合有效地提供最低NOx和烟气排放的组合， 由此柴油发动机的NOx和烟气排放分别减少至少10％和15％。

公开(公告)号：WO2011127324A2

公开(公告)日：2011-10-13

申请号：PCT/US2011/031640

申请日：2011-04-07

Applicant: JN BIOSCIENCES, LLC ,  TSO, J. Yun ,  TSURUSHITA, Naoya ,  LANDOLFI, Nicholas F. ,  KUMAR, Shankar

Inventor： TSO, J. Yun ,  TSURUSHITA, Naoya ,  LANDOLFI, Nicholas F. ,  KUMAR, Shankar

IPC: C07K16/28 ,  C07K16/18 ,  C07K16/46 ,  A61K39/395 ,  A61P35/00 ,  A61P29/00

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76

Abstract: The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.

Abstract translation: 本发明提供了特异性结合CD122的单克隆抗体，CD122是IL-2和IL-15受体的一个组分。 通过抑制这些细胞因子与其受体的结合，单克隆抗体具有对IL-2和IL-15介导的功能的显着抑制的能力。 除了其它应用之外，单克隆抗体可用于抑制不期望的免疫应答或癌症的治疗。

公开(公告)号：WO2011053819A2

公开(公告)日：2011-05-05

申请号：PCT/US2010/054790

申请日：2010-10-29

Applicant: BP CORPORATION NORTH AMERICA INC. ,  CUMMINS INC. ,  XU, Yi ,  WOLF, Leslie ,  KUMAR, Shankar ,  STANTON, Donald, W. ,  FRAZIER, Timothy, R. ,  BUNTING, Bruce, G.

Inventor： XU, Yi ,  WOLF, Leslie ,  KUMAR, Shankar ,  STANTON, Donald, W. ,  FRAZIER, Timothy, R. ,  BUNTING, Bruce, G.

IPC: F01N3/10

CPC classification number: F02D41/0025 ,  C10L1/08 ,  F02D19/061 ,  F02D19/0649 ,  F02D19/087 ,  F02M26/23 ,  F02M31/13 ,  F02M2200/95 ,  Y02T10/36

Abstract: A diesel fuel composition is disclosed, as well as a method for reducing NOx and smoke emissions from a diesel engine at minimum fuel consumption which comprises adding to the diesel engine at least one diesel fuel or blending component for a diesel fuel which has a combination of a low T50 in the range of from 190°C to 28O°C, a high cetane number in the range of from 31 to 60, and optionally a high distillation curve slope in the range of from 58°C to 140°C, which combination is effective to afford a combination of the lowest NO x and smoke emissions at the lowest fuel consumption at independent engine control values for the diesel engine that are optimum to afford production of a combination of the lowest NOx and smoke emissions at the lowest fuel consumption, whereby the NOx and smoke emissions from the diesel engine are reduced by at least 10% and 15%, respectively.

Abstract translation: 公开了一种柴油燃料组合物，以及用于以最小燃料消耗量从柴油发动机减少NOx和烟雾排放的方法，该方法包括向柴油发动机添加至少一种用于柴油燃料的柴油燃料或混合组分， 在190℃至280℃的范围内的低T50，在31至60的范围内的高十六烷值，以及可选地在58℃至140℃的范围内的高蒸馏曲线斜率，其中 组合有效地在柴油机的独立发动机控制值下以最低燃料消耗提供最低NOx和烟雾排放的组合，其最适于在最低燃料消耗下提供最低NOx和烟雾排放的组合的生产， 从而柴油发动机的NOx和烟雾排放量分别降低了10％和15％。

公开(公告)号：WO2005014653A3

公开(公告)日：2005-06-16

申请号：PCT/US2004006343

申请日：2004-02-26

Applicant: PROTEIN DESIGN LABS INC ,  TSURUSHITA NAOYA ,  KUMAR SHANKAR ,  VASQUEZ MAXIMILIANO

Inventor： TSURUSHITA NAOYA ,  KUMAR SHANKAR ,  VASQUEZ MAXIMILIANO

IPC: A61P37/00 ,  C07K16/24 ,  C07K16/28 ,  C12N15/13 ,  C07K16/46 ,  A61K39/395 ,  C12N5/10 ,  C12N15/63

CPC classification number: C07K16/244 ,  C07K16/2854 ,  C07K2317/23 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2319/00

Abstract: The present invention concerns chicken antibodies and humanized chicken antibodies and the method of making such antibodies. In a particular embodiment, it provides humanized chicken antibodies that bind to or neutralize human and/or mouse proteins, such IL-12 or L-selectin. It also provides the method for the prevention or treatment of autoimmune diseases by using such antibodies.

Abstract translation: 本发明涉及鸡抗体和人源化鸡抗体以及制备这种抗体的方法。 在一个具体的实施方案中，它提供了结合或中和人和/或小鼠蛋白如IL-12或L-选择蛋白的人源化鸡抗体。 它还提供了通过使用这种抗体来预防或治疗自身免疫疾病的方法。

公开(公告)号：WO2013028231A1

公开(公告)日：2013-02-28

申请号：PCT/US2012/024570

申请日：2012-02-09

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  LIU, Yong-Jun ,  VOO, Kui Shin ,  BOVER, Laura ,  TSURUSHITA, Naoya ,  TSO, J. Yun ,  KUMAR, Shankar

Inventor： LIU, Yong-Jun ,  VOO, Kui Shin ,  BOVER, Laura ,  TSURUSHITA, Naoya ,  TSO, J. Yun ,  KUMAR, Shankar

IPC: C07K16/28 ,  C12N15/13 ,  C12N15/63 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/205 ,  A61K2039/505 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92

Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full- length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Abstract translation: 公开了与人OX40特异性结合的人抗体，优选重组人抗体，人源化和嵌合。 优选的抗体对OX40受体具有高亲和力，并在体外和体内激活受体。 抗体可以是全长抗体或其抗原结合部分。 抗体或抗体部分可用于调节受体活性，例如在患有OX40活性有害的病症的人类受试者中。 提供用于表达重组人抗体的核酸，载体和宿主细胞，并提供合成重组人抗体的方法。

公开(公告)号：WO2012027328A3

公开(公告)日：2012-03-01

申请号：PCT/US2011/048752

申请日：2011-08-23

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  LIU, Yong-Jun ,  VOO, Kui Shin ,  BOVER, Laura ,  TSURUSHITA, Naoya ,  TSO, J., Yun ,  KUMAR, Shankar

Inventor： LIU, Yong-Jun ,  VOO, Kui Shin ,  BOVER, Laura ,  TSURUSHITA, Naoya ,  TSO, J., Yun ,  KUMAR, Shankar

IPC: C07K16/28 ,  C12N15/13 ,  A61K39/395 ,  A61P35/00

Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

公开(公告)号：WO2010003117A3

公开(公告)日：2010-11-18

申请号：PCT/US2009049613

申请日：2009-07-02

Applicant: GOOGLE INC ,  MACHEREY WOLFGANG ,  KUMAR SHANKAR ,  TROMBLE ROY W ,  OCH FRANZ JOSEF ,  THAYER IGNACIO E ,  USZKOREIT JAKOB

Inventor： MACHEREY WOLFGANG ,  KUMAR SHANKAR ,  TROMBLE ROY W ,  OCH FRANZ JOSEF ,  THAYER IGNACIO E ,  USZKOREIT JAKOB

IPC: G06F17/00 ,  G06F9/06 ,  G06F11/00 ,  G06F17/20

CPC classification number: G06F17/2818

Abstract: Methods, systems, and apparatus, including computer program products, for language translation are disclosed. In one implementation, a method is provided. The method includes accessing a hypothesis space; performing decoding on the hypothesis space to obtain a translation hypothesis that minimizes an expected error in classification calculated relative to an evidence space; and providing the obtained translation hypothesis for use by a user as a suggested translation in a target translation.

公开(公告)号：WO2007143701A8

公开(公告)日：2009-07-23

申请号：PCT/US2007070541

申请日：2007-06-06

Applicant: PROGENICS PHARM INC ,  NAGASHIMA KIRSTEN A ,  OLSON WILLIAM C ,  MADDON PAUL J ,  KODURI RAJU ,  DONOVAN GERALD P ,  TSURUSHITA NAOYA ,  TSO J ,  KUMAR SHANKAR

Inventor： NAGASHIMA KIRSTEN A ,  OLSON WILLIAM C ,  MADDON PAUL J ,  KODURI RAJU ,  DONOVAN GERALD P ,  TSURUSHITA NAOYA ,  TSO J ,  KUMAR SHANKAR

IPC: C07K16/10 ,  A61K39/42 ,  A61K51/10 ,  C07K16/46 ,  C12N5/12 ,  C12N15/13 ,  C12N15/85

CPC classification number: C07K16/109 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides potent HCV neutralizing monoclonal antibodies and portions thereof that inhibit entry of HCV into susceptible cells. The neutralizing monoclonal antibodies of the invention are broadly reactive against HCV of different genotypes, including genotypes 1 and 2. A particular monoclonal antibody, designated PA-29, does not bind soluble or independently-expressed HCV E1 and E2 envelope glycoproteins. A hybridoma cell line producing the PA-29 monoclonal antibody has been deposited under ATCC Accession No. PTA-7632. The described monoclonal antibodies, including PA-29 and humanized and chimeric forms thereof, serve as HCV antagonists for use in therapeutic and prophylactic methods of treating and preventing HIV infection of susceptible cells, in methods of blocking HCV entry into susceptible cells and in methods of diagnosis and detection of HCV in a sample of a subject and within a subject.

Abstract translation: 本发明提供了有效的HCV中和单克隆抗体及其部分，其抑制HCV进入敏感细胞。 本发明的中和单克隆抗体对不同基因型的HCV具有广泛的反应性，包括基因型1和2.特异性单克隆抗体（称为PA-29）不结合可溶性或独立表达的HCV E1和E2包膜糖蛋白。 产生PA-29单克隆抗体的杂交瘤细胞系已经以ATCC登录号PTA-7632保藏。 描述的单克隆抗体，包括PA-29及其人源化和嵌合形式，用作用于治疗和预防感染细胞的HIV感染的治疗和预防方法的HCV拮抗剂，在阻断HCV进入易感细胞的方法中 诊断和检测受试者和受试者内的HCV样本。

公开(公告)号：WO2007095729A8

公开(公告)日：2009-07-16

申请号：PCT/CA2007000254

申请日：2007-02-22

Applicant: ARIUS RES INC ,  YOUNG DAVID S F ,  FINDLAY HELEN P ,  HAHN SUSAN E ,  DACRUZ LUIS A G ,  SAYEGH DAAD ,  ROGERS KRISTIAN ,  KUMAR SHANKAR ,  HINTON PAUL

Inventor： YOUNG DAVID S F ,  FINDLAY HELEN P ,  HAHN SUSAN E ,  DACRUZ LUIS A G ,  SAYEGH DAAD ,  ROGERS KRISTIAN ,  KUMAR SHANKAR ,  HINTON PAUL

IPC: C12N5/12 ,  A61K39/395 ,  A61K47/48 ,  A61P35/00 ,  C07K16/30 ,  G01N33/567 ,  G01N33/574

CPC classification number: G01N33/57492 ,  A61K47/6849 ,  A61K47/6851 ,  A61K51/1027 ,  A61K51/1045 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/92 ,  G01N33/56966 ,  G01N33/5743 ,  G01N2333/70596

Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDlVIAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

Abstract translation: 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CD1VIAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。